Benzinga | Nov 16, 2021 07:20AM EST

SVB Leerink Downgrades Landos Biopharma to Market Perform, Lowers Price Target to $16

SVB Leerink analyst Thomas Smith downgrades Landos Biopharma (NASDAQ:LABP) from Outperform to Market Perform and lowers the price target from $20 to $16.